NO20014657L - Preparations and Methods to Affect High Density Lipoprotein (HDL) Cholesterol and Apolipoprotein A1, Verylow Density Lipoprotein (VLDL) Cholesterol and Low Density Lipoprotein (LDL) Cholesterol - Google Patents
Preparations and Methods to Affect High Density Lipoprotein (HDL) Cholesterol and Apolipoprotein A1, Verylow Density Lipoprotein (VLDL) Cholesterol and Low Density Lipoprotein (LDL) CholesterolInfo
- Publication number
- NO20014657L NO20014657L NO20014657A NO20014657A NO20014657L NO 20014657 L NO20014657 L NO 20014657L NO 20014657 A NO20014657 A NO 20014657A NO 20014657 A NO20014657 A NO 20014657A NO 20014657 L NO20014657 L NO 20014657L
- Authority
- NO
- Norway
- Prior art keywords
- cholesterol
- density lipoprotein
- verylow
- vldl
- apolipoprotein
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/18—Carboxylic ester hydrolases (3.1.1)
- C12N9/20—Triglyceride splitting, e.g. by means of lipase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/277,401 US7008776B1 (en) | 1996-12-06 | 1999-03-26 | Compositions and methods for effecting the levels of high density lipoprotein (HDL) cholesterol and apolipoprotein AI very low density lipoprotein (VLDL) cholesterol and low density lipoprotein (LDL) cholesterol |
PCT/US2000/007870 WO2000057837A2 (en) | 1999-03-26 | 2000-03-24 | Compositions and methods for effecting the levels of cholesterol |
Publications (3)
Publication Number | Publication Date |
---|---|
NO20014657D0 NO20014657D0 (en) | 2001-09-25 |
NO20014657L true NO20014657L (en) | 2001-11-21 |
NO331779B1 NO331779B1 (en) | 2012-03-26 |
Family
ID=23060703
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20014657A NO331779B1 (en) | 1999-03-26 | 2001-09-25 | Methods for determining whether a test compound can inhibit the enzymatic reaction between the LIPG polypeptide and HDL cholesterol and apolipoprotein A1 or promote the enzymatic reaction between the LIPG polypeptide and VLDL cholesterol or LDL cholesterol |
NO20100214A NO331784B1 (en) | 1999-03-26 | 2010-02-11 | Use of a ribozyme for the preparation of a composition capable of reducing the enzymatic activity of LIPG in a patient. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20100214A NO331784B1 (en) | 1999-03-26 | 2010-02-11 | Use of a ribozyme for the preparation of a composition capable of reducing the enzymatic activity of LIPG in a patient. |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP1171078A4 (en) |
JP (1) | JP2002540127A (en) |
KR (2) | KR20050044812A (en) |
AU (1) | AU776684B2 (en) |
BR (1) | BR0009333A (en) |
CA (1) | CA2363486C (en) |
HK (1) | HK1043309A1 (en) |
IL (2) | IL145526A0 (en) |
MX (1) | MXPA01009727A (en) |
NO (2) | NO331779B1 (en) |
NZ (2) | NZ531180A (en) |
WO (1) | WO2000057837A2 (en) |
ZA (1) | ZA200107598B (en) |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7507808B2 (en) * | 2002-12-12 | 2009-03-24 | Isis Pharmaceuticals, Inc. | Modulation of endothelial lipase expression |
EP1976567B1 (en) | 2005-12-28 | 2020-05-13 | The Scripps Research Institute | Natural antisense and non-coding rna transcripts as drug targets |
US8927511B2 (en) | 2008-12-04 | 2015-01-06 | Curna, Inc. | Treatment of vascular endothelial growth factor (VEGF) related diseases by inhibition of natural antisense transcript to VEGF |
ES2629630T3 (en) | 2008-12-04 | 2017-08-11 | Curna, Inc. | Treatment of diseases related to erythropoietin (EPO) by inhibiting the natural antisense transcript to EPO |
EP2370582B1 (en) | 2008-12-04 | 2017-05-10 | CuRNA, Inc. | Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene |
ES2560107T3 (en) | 2009-02-12 | 2016-02-17 | Curna, Inc. | Treatment of diseases related to brain-derived neurotrophic factor (BDNF) by inhibition of natural antisense transcript for BDNF |
CA2755409C (en) | 2009-03-16 | 2019-04-30 | Joseph Collard | Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2 |
JP5904935B2 (en) | 2009-03-17 | 2016-04-20 | クルナ・インコーポレーテッド | Treatment of DLK1-related diseases by suppression of natural antisense transcripts against Delta-like 1 homolog (DLK1) |
KR101722541B1 (en) | 2009-05-06 | 2017-04-04 | 큐알엔에이, 인크. | Treatment of tristetraproline(ttp) related diseases by inhibition of natural antisense transcript to ttp |
CN102459596B (en) | 2009-05-06 | 2016-09-07 | 库尔纳公司 | By suppression therapy lipid transfer and the metabolic gene relevant disease of the natural antisense transcript for lipid transfer and metabolic gene |
CA2761248C (en) | 2009-05-08 | 2023-03-14 | Joseph Collard | Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to dmd family |
ES2664590T3 (en) | 2009-05-18 | 2018-04-20 | Curna, Inc. | Treatment of diseases related to reprogramming factors by inhibition of the natural antisense transcript to a reprogramming factor |
US8895527B2 (en) | 2009-05-22 | 2014-11-25 | Curna, Inc. | Treatment of transcription factor E3 (TFE3) and insulin receptor substrate 2(IRS2) related diseases by inhibition of natural antisense transcript to TFE3 |
WO2010138806A2 (en) | 2009-05-28 | 2010-12-02 | Curna, Inc. | Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene |
US8951981B2 (en) | 2009-06-16 | 2015-02-10 | Curna, Inc. | Treatment of paraoxonase 1 (PON1) related diseases by inhibition of natural antisense transcript to PON1 |
JP5944311B2 (en) | 2009-06-16 | 2016-07-05 | クルナ・インコーポレーテッド | Treatment of collagen gene-related diseases by suppression of natural antisense transcripts against collagen genes |
JP6073133B2 (en) | 2009-06-24 | 2017-02-01 | クルナ・インコーポレーテッド | Treatment of TNFR2-related diseases by suppression of natural antisense transcripts against tumor necrosis factor receptor 2 (TNFR2) |
EP2446037B1 (en) | 2009-06-26 | 2016-04-20 | CuRNA, Inc. | Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene |
US20120252869A1 (en) | 2009-07-24 | 2012-10-04 | Opko Curna, Llc | Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt) |
CN102762731B (en) | 2009-08-05 | 2018-06-22 | 库尔纳公司 | By inhibiting to treat insulin gene (INS) relevant disease for the natural antisense transcript of insulin gene (INS) |
CN104313027B (en) | 2009-08-11 | 2018-11-20 | 库尔纳公司 | By inhibiting the natural antisense transcript of adiponectin (ADIPOQ) to treat adiponectin (ADIPOQ) related disease |
KR101805213B1 (en) | 2009-08-21 | 2017-12-06 | 큐알엔에이, 인크. | Treatment of 'c terminus of hsp70-interacting protein' (chip) related diseases by inhibition of natural antisense transcript to chip |
WO2011031482A2 (en) | 2009-08-25 | 2011-03-17 | Curna, Inc. | Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap |
CN102791861B (en) | 2009-09-25 | 2018-08-07 | 库尔纳公司 | FLG relevant diseases are treated by adjusting expression and the activity of Filaggrin (FLG) |
ES2661813T3 (en) | 2009-12-16 | 2018-04-04 | Curna, Inc. | Treatment of diseases related to membrane transcription factor peptidase, site 1 (mbtps1) by inhibition of the natural antisense transcript to the mbtps1 gene |
JP5934106B2 (en) | 2009-12-23 | 2016-06-15 | カッパーアールエヌエー,インコーポレイテッド | Treatment of HGF-related diseases by inhibition of natural antisense transcripts against hepatocyte growth factor (HGF) |
CA2782375C (en) | 2009-12-23 | 2023-10-31 | Opko Curna, Llc | Treatment of uncoupling protein 2 (ucp2) related diseases by inhibition of natural antisense transcript to ucp2 |
EP2519634B1 (en) | 2009-12-29 | 2016-06-01 | CuRNA, Inc. | TREATMENT OF TUMOR PROTEIN 63 (p63) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO p63 |
US8921334B2 (en) | 2009-12-29 | 2014-12-30 | Curna, Inc. | Treatment of nuclear respiratory factor 1 (NRF1) related diseases by inhibition of natural antisense transcript to NRF1 |
WO2011082281A2 (en) | 2009-12-31 | 2011-07-07 | Curna, Inc. | Treatment of insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to irs2 and transcription factor e3 (tfe3) |
KR101878501B1 (en) | 2010-01-04 | 2018-08-07 | 큐알엔에이, 인크. | Treatment of interferon regulatory factor 8 (irf8) related diseases by inhibition of natural antisense transcript to irf8 |
KR101853509B1 (en) | 2010-01-06 | 2018-04-30 | 큐알엔에이, 인크. | Treatment of Pancreatic Developmental Gene Related Diseases By Inhibition of Natural Antisense Transcript to A Pancreatic Developmental Gene |
ES2664866T3 (en) | 2010-01-11 | 2018-04-23 | Curna, Inc. | Treatment of diseases related to sex hormone binding globulin (shbg) by inhibition of the natural antisense transcript to shbg |
CN102782135A (en) | 2010-01-25 | 2012-11-14 | 库尔纳公司 | Treatment of RNase H1 related diseases by inhibition of natural antisense transcript to RNase H1 |
US8962586B2 (en) | 2010-02-22 | 2015-02-24 | Curna, Inc. | Treatment of pyrroline-5-carboxylate reductase 1 (PYCR1) related diseases by inhibition of natural antisense transcript to PYCR1 |
KR101877065B1 (en) | 2010-04-02 | 2018-07-10 | 큐알엔에이, 인크. | Treatment of colony-stimulating factor 3 (csf3) related diseases by inhibition of natural antisense transcript to csf3 |
CN102858979B (en) | 2010-04-09 | 2018-01-26 | 库尔纳公司 | FGF21 relevant diseases are treated by suppressing the natural antisense transcript of FGF2 1 (FGF21) |
WO2011139387A1 (en) | 2010-05-03 | 2011-11-10 | Opko Curna, Llc | Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt) |
TWI586356B (en) | 2010-05-14 | 2017-06-11 | 可娜公司 | Treatment of par4 related diseases by inhibition of natural antisense transcript to par4 |
RU2620978C2 (en) | 2010-05-26 | 2017-05-30 | Курна, Инк. | Treatment of diseases associated with methionine sulfoxide reductase a (msra), by msra natural antisense transcript inhibition |
NO2576783T3 (en) | 2010-05-26 | 2018-04-28 | ||
JP6023705B2 (en) | 2010-06-23 | 2016-11-09 | カッパーアールエヌエー,インコーポレイテッド | Treatment of SCNA-related diseases by inhibition of natural antisense transcripts on sodium channels, voltage-gated, alpha subunit (SCNA) |
US8980860B2 (en) | 2010-07-14 | 2015-03-17 | Curna, Inc. | Treatment of discs large homolog (DLG) related diseases by inhibition of natural antisense transcript to DLG |
US8993533B2 (en) | 2010-10-06 | 2015-03-31 | Curna, Inc. | Treatment of sialidase 4 (NEU4) related diseases by inhibition of natural antisense transcript to NEU4 |
CA2815212A1 (en) | 2010-10-22 | 2012-04-26 | Curna, Inc. | Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua |
US10000752B2 (en) | 2010-11-18 | 2018-06-19 | Curna, Inc. | Antagonat compositions and methods of use |
KR102010598B1 (en) | 2010-11-23 | 2019-08-13 | 큐알엔에이, 인크. | Treatment of nanog related diseases by inhibition of natural antisense transcript to nanog |
JP6188686B2 (en) | 2011-06-09 | 2017-08-30 | カッパーアールエヌエー,インコーポレイテッド | Treatment of FXN-related diseases by inhibition of natural antisense transcripts to frataxin (FXN) |
CN108272782B (en) | 2011-09-06 | 2021-04-23 | 库尔纳公司 | Use of small molecules in preparation of medicine for treating Dravet syndrome or generalized epilepsy with febrile convulsion adjunctive disease |
CN110438125A (en) | 2012-03-15 | 2019-11-12 | 科纳公司 | By inhibiting the natural antisense transcript of brain derived neurotrophic factor (BDNF) to treat BDNF related disease |
CN102628060A (en) * | 2012-03-22 | 2012-08-08 | 北京济福霖生物技术有限公司 | Production method of low-fat milk |
US9695462B2 (en) | 2012-11-05 | 2017-07-04 | Shionogi & Co., Ltd. | Method for evaluation of drug efficacy of a medicine having a therapeutic or preventive effect against a disease related to EL activity and a method for screening an inhibitor of EL activity |
WO2014142182A1 (en) * | 2013-03-14 | 2014-09-18 | 塩野義製薬株式会社 | Monoclonal antibody inhibiting enzymatic activity of endothelial lipase |
TWI734410B (en) | 2014-09-11 | 2021-07-21 | 日商塩野義製藥股份有限公司 | Humanized monoclonal antibody, inhibiting the enzymatic activity of vascular endothelial lipase |
EP4284335A1 (en) | 2021-02-01 | 2023-12-06 | RegenxBio Inc. | Gene therapy for neuronal ceroid lipofuscinoses |
WO2023008337A1 (en) * | 2021-07-26 | 2023-02-02 | ピューロテックバイオ株式会社 | Anti-hepatitis b virus agent targeting host factor lipg |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994013791A1 (en) * | 1992-12-04 | 1994-06-23 | Innovir Laboratories, Inc. | Regulatable nucleic acid therapeutic and methods of use thereof |
SK287687B6 (en) * | 1996-12-06 | 2011-06-06 | Aventis Pharmaceuticals Inc. | Polypeptides encoded by a human lipase-like gene, compositions and methods |
AU1941899A (en) * | 1997-12-19 | 1999-07-12 | Progenitor, Inc. | A lipase expressed in endothelial cells and methods for its use |
-
2000
- 2000-03-24 BR BR0009333-5A patent/BR0009333A/en not_active Application Discontinuation
- 2000-03-24 NZ NZ531180A patent/NZ531180A/en not_active IP Right Cessation
- 2000-03-24 KR KR1020057005114A patent/KR20050044812A/en active Search and Examination
- 2000-03-24 JP JP2000607588A patent/JP2002540127A/en active Pending
- 2000-03-24 WO PCT/US2000/007870 patent/WO2000057837A2/en active IP Right Grant
- 2000-03-24 EP EP00918362A patent/EP1171078A4/en not_active Ceased
- 2000-03-24 CA CA2363486A patent/CA2363486C/en not_active Expired - Fee Related
- 2000-03-24 KR KR1020017012300A patent/KR100887164B1/en not_active IP Right Cessation
- 2000-03-24 NZ NZ51435000A patent/NZ514350A/en not_active IP Right Cessation
- 2000-03-24 IL IL14552600A patent/IL145526A0/en unknown
- 2000-03-24 MX MXPA01009727A patent/MXPA01009727A/en active IP Right Grant
- 2000-03-24 AU AU39187/00A patent/AU776684B2/en not_active Ceased
-
2001
- 2001-09-14 ZA ZA200107598A patent/ZA200107598B/en unknown
- 2001-09-20 IL IL145526A patent/IL145526A/en not_active IP Right Cessation
- 2001-09-25 NO NO20014657A patent/NO331779B1/en not_active IP Right Cessation
-
2002
- 2002-06-28 HK HK02104818.0A patent/HK1043309A1/en unknown
-
2010
- 2010-02-11 NO NO20100214A patent/NO331784B1/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
IL145526A0 (en) | 2002-06-30 |
KR20050044812A (en) | 2005-05-12 |
JP2002540127A (en) | 2002-11-26 |
WO2000057837A9 (en) | 2001-10-18 |
HK1043309A1 (en) | 2002-09-13 |
EP1171078A2 (en) | 2002-01-16 |
WO2000057837A8 (en) | 2001-09-27 |
NO331779B1 (en) | 2012-03-26 |
NO331784B1 (en) | 2012-03-26 |
NZ531180A (en) | 2005-06-24 |
ZA200107598B (en) | 2003-05-28 |
NO20100214L (en) | 2001-11-21 |
KR20020029651A (en) | 2002-04-19 |
NO20014657D0 (en) | 2001-09-25 |
IL145526A (en) | 2010-11-30 |
AU776684B2 (en) | 2004-09-16 |
WO2000057837A3 (en) | 2001-01-25 |
WO2000057837A2 (en) | 2000-10-05 |
EP1171078A4 (en) | 2002-11-06 |
AU3918700A (en) | 2000-10-16 |
KR100887164B1 (en) | 2009-03-10 |
CA2363486C (en) | 2012-12-18 |
CA2363486A1 (en) | 2000-10-05 |
MXPA01009727A (en) | 2002-07-22 |
NZ514350A (en) | 2004-12-24 |
BR0009333A (en) | 2002-01-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20014657L (en) | Preparations and Methods to Affect High Density Lipoprotein (HDL) Cholesterol and Apolipoprotein A1, Verylow Density Lipoprotein (VLDL) Cholesterol and Low Density Lipoprotein (LDL) Cholesterol | |
NO20016114L (en) | Preparations and Methods to Increase Cholesterol Elevation and Raise HDL Using ATP Binding Cartridge Carrier Protein ABC1 | |
NO984524D0 (en) | Amphipathic molecules such as cholesterol and other lipid uptake inhibitors | |
AU2002212717A1 (en) | Test piece for assaying high density lipoprotein (hdl) cholesterol | |
AU1856997A (en) | Method for raising hdl cholesterol levels | |
AU2001241000A1 (en) | System and method for computer searching | |
AU2585301A (en) | System and method for trusted self-billing for utilities | |
AU2001275539A1 (en) | Method for authenticating and securing integrated bookstore entries | |
AU2001245401A1 (en) | Hydrazones and analogs as cholesterol lowering agents | |
AU2001266578A1 (en) | System and method for providing access to forms and maintaining the data used tocomplete the forms | |
NO20014029D0 (en) | Organic sol and solid compound based on cerium oxide and an amphiphilic compound and process for preparation | |
EP1212065A4 (en) | Compositions and methods for raising hdl cholesterol levels | |
AU3239800A (en) | Method and apparatus for improving access to literature | |
AU5021100A (en) | Method and apparatus for creating and executing internet based lectures using public domain web pages | |
NO20004104D0 (en) | Preparations comprising viruses and methods for concentrating virus preparations | |
AU4880801A (en) | System and method for supporting businesses | |
AU2001278926A1 (en) | Attachments for support members and methods therefor | |
TWI319009B (en) | Pretreatment method of samples for cholesterol quantitation, and quantitation method of cholesterol in specific lipoprotein by the use of the pretreatme | |
DE69931279D1 (en) | METHOD AND COMPOSITIONS FOR REDUCING THE CHOLESTEROL MIRROR IN PLASMA | |
AU1960600A (en) | Method and apparatus for minimizing differential power attacks on processors | |
NO20005433D0 (en) | Human BMP-7 promoter and method to explore bone related substance using the same | |
AU2001268601A1 (en) | Methods and apparatus for reducing vibrations induced within fan assemblies | |
EP1059579A3 (en) | Information processor and method for switching register files | |
AU3074099A (en) | Method and composition for lowering low density lipoprotein cholesterol | |
AU6595700A (en) | Method and apparatus for operating virtual computer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |